Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Caffo O, Ortega C, Nolè F, Gasparro D, Mucciarini C, Aieta M, Zagonel V, Iacovelli R, De Giorgi U, Facchini G, Veccia A, Palesandro E, Verri E, Buti S, Razzini G, Bozza G, Maruzzo M, Ciccarese C, Schepisi G, Rossetti S, Maines F, Kinspergher S, Fratino L, Ermacora P, Nicodemo M, Giordano M, Sartori D, Scapoli D, Sabbatini R, Lo Re G, Morelli F, D'Angelo A, Vittimberga I, Lippe P, Carrozza F, Messina C, Galli L, Valcamonico F, Porta C, Pappagallo G, Aglietta M. Caffo O, et al. Among authors: pappagallo g. Eur J Cancer. 2021 Sep;155:56-63. doi: 10.1016/j.ejca.2021.06.016. Epub 2021 Aug 3. Eur J Cancer. 2021. PMID: 34358777 Clinical Trial.
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Caffo O, Lo Re G, Sava T, Buti S, Sacco C, Basso U, Zustovich F, Lodde M, Perin A, Facchini G, Veccia A, Maines F, Barile C, Fratino L, Gernone A, De Vivo R, Pappagallo GL, Galligioni E. Caffo O, et al. Among authors: pappagallo gl. Future Oncol. 2015;11(6):965-73. doi: 10.2217/fon.14.284. Future Oncol. 2015. PMID: 25760977 Clinical Trial.
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
Caffo O, Wissing M, Bianchini D, Bergman A, Thomsen FB, Schmid S, Yu EY, Bournakis E, Sella A, Zagonel V, De Giorgi U, Tucci M, Gelderblom H, Galli L, Pappagallo G, Bria E, Sperduti I, Oudard S; CASTOR study investigators. Caffo O, et al. Among authors: pappagallo g. Clin Genitourin Cancer. 2020 Feb;18(1):69-76.e4. doi: 10.1016/j.clgc.2019.09.010. Epub 2019 Sep 27. Clin Genitourin Cancer. 2020. PMID: 31767448
Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document.
Lapini A, Caffo O, Pappagallo G, Iacovelli R, D'Angelillo RM, Vavassori V, Ceccarelli R, Bracarda S, Jereczek-Fossa BA, Da Pozzo L, Conti GN. Lapini A, et al. Among authors: pappagallo g. Cancers (Basel). 2019 Dec 1;11(12):1908. doi: 10.3390/cancers11121908. Cancers (Basel). 2019. PMID: 31805687 Free PMC article.
Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
Paccagnella A, Favaretto A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S, Panozzo M, Chieco-Bianchi L, et al. Paccagnella A, et al. Among authors: pappagallo g. Cancer. 1993 Aug 1;72(3):697-706. doi: 10.1002/1097-0142(19930801)72:3<697::aid-cncr2820720312>3.0.co;2-u. Cancer. 1993. PMID: 8392903 Clinical Trial.
105 results